
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2018

IMPRIMIS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35814
(Commission
File Number)

45-0567010
(IRS Employer
Identification No.)

12264 El Camino Real, Suite 350
San Diego, CA
(Address of principal executive offices)

92130
(Zip Code)

Registrant's telephone number, including area code: **(858) 704-4040**

N/A

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 7.01. Regulation FD Disclosure

Attached as Exhibit 99.1 to this Item 7.01 is a presentation of Imprimis Pharmaceuticals, Inc. (the “Company”), that is being used by the management of the Company at investor conferences and at meetings describing the Company.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits**(d) Exhibits**

99.1 [Imprimis Pharmaceuticals, Inc. Corporate Presentation dated January 2018](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Imprimis Pharmaceuticals, Inc.

Date: January 9, 2018

By: /s/ Andrew R. Boll

Name: Andrew R. Boll

Title: Chief Financial Officer



NASDAQ: IMMY
January 2018




Safe Harbor

This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Imprimis Pharmaceuticals, Inc.’s (the “Company” or “Imprimis”) expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company’s ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company’s formulations and challenges related to the marketing of the Company’s formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn and raise additional funds when necessary; its ability to generate profits from sales of its formulations; risks related to research and development activities; its estimates of the current and potential market size for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Imprimis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Our compounded formulations are not FDA approved.

Introduction to Imprimis Pharmaceuticals

- Imprimis is one of the largest specialized compounded drug businesses in the US
- Serve unmet needs by compounding new drugs from bulk active drug ingredients
- IP focused with 60+ formulation composition and method patent filings
- Monetize IP portfolio through compounding businesses and 505(b)(2) spin-outs

**Imprimis Owns
Four Unique
Pharmaceutical
Businesses**



imprimis 

- 100% ownership
- Largest **ophthalmology** compounding business in the US
- Operate under 2013 Federal drug compounding law

PARK
COMPOUNDING

- 100% ownership
- Custom compounded drugs; focused on integrative medicine
- Incubator for new drug formulation ideas

eTon
pharmaceuticals

- 3.5M shares; largest shareholder
- Specialty pharma business utilizing the 505(b)(2) pathway

surface
pharmaceuticals

- 3.75M shares; largest shareholder
- Ocular surface disease-focused 505(b)(2) specialty pharma co

-  Compounding Companies
-  FDA 505(b)(2) Companies






imprimis ^{Rx} Ophthalmology



imprimis_{Rx} Value Chain



Physician and Institution Benefits

- No insurance company, pharmacy benefit manager (PBM), wholesaler or distributor middlemen
- No formulary rejections, discount cards or rebates
- No payment submittals, investigations or PBM clawbacks
- Direct access to drug formulators to meet their needs

Ophthalmology Market Data

	Opportunity in US	FY 2021 Goals	Current Progress	How To Get There
Ophthalmic Surgery	<ul style="list-style-type: none"> \$1 billion drug market ~4.6M ocular surgeries and other procedures¹⁻¹⁴ Demographic growth in the overall market ~6% per yr 	<ul style="list-style-type: none"> 525,000 procedures 13% market share Increase revenue to >\$75 per surgery 	<ul style="list-style-type: none"> 400,000+ per year ~\$45 per surgery Launched in 2014 	<ul style="list-style-type: none"> Broaden product portfolio to increase average revenue per surgery
Glaucoma	<ul style="list-style-type: none"> \$2 billion drug market 19+ million targeted prescriptions³ 4 million Americans¹⁵ 	<ul style="list-style-type: none"> 600,000 prescription equivalents 3% prescription share \$65 per monthly prescription 	<ul style="list-style-type: none"> Launched in Q2-2017 Exceeding internal refill rate goals thus far 	<ul style="list-style-type: none"> Unique compounded formulations combine drugs into single bottle as compared to multi bottle regimens Approx. 2 of 3 current physician customers treat glaucoma³
Dry Eye	<ul style="list-style-type: none"> \$2 billion drug market 4 million prescriptions³ Estimated 30 million Americans suffer from some form of dry eye¹⁶ 	<ul style="list-style-type: none"> 400,000 prescription equivalents 10% prescription share \$49 per monthly prescription 	<ul style="list-style-type: none"> Launched in Q4-2017 	<ul style="list-style-type: none"> Only 1M patients on existing therapies and millions more not satisfied with current options Cost effective offerings may expand the market to many not on therapy

imprimis^{Rx} Formulations For Individual Patients



Proprietary formulations include:

Latanoprost (preservative-free)

Timolol + latanoprost

Timolol + brimonidine + dorzolamide

Timolol + brimon. + dorzol. + latanoprost

Chondroitin sulfate + 0.1% cyclosporine

What is it:

- Chronic care compounded ophthalmic drugs

Why is it important:

- Compounded solutions for unmet market needs
- Value Proposition:
 - Combine multiple medicines into one bottle
 - Can be preservative free
 - Lower cost than commercial drugs
- IP strategy to create durable market positioning

What is the opportunity:

- Grow adoption and prescription share of our recently launched compounded formulations
- Leverage growing customer base

imprimis^{Rx} Formulations For Office Use



Proprietary formulations include:

Prednisolone acetate + gatifloxacin

Prednisolone acetate + gatifloxacin + bromfenac

Prednisolone acetate + bromfenac

Midazolam + ketamine HCl + ondansetron

What is it:

- Cost effective suite of preoperative, intraoperative, and postoperative compounded formulations
- Patented and patent-pending formulations include combination eye drops, injectables and troches

Why is it important:

- Made in an FDA-registered outsourcing facility
- Highest federal quality standards (cGMP)
- IP positioning ensures that no outsourcing facility competitor can offer a comparable portfolio

What is the opportunity:

- Growing market with aging population (4.6M ocular surgeries annually in U.S.¹⁻⁴)
- Introduce new formulations in 2018 to increase revenue per order/surgery



Other Imprimis Businesses

PARK
COMPOUNDING

eTon
pharmaceuticals


surface
pharmaceuticals, llc



Eton Pharmaceuticals, Inc. Spin-Out



p h a r m a c e u t i c a l s



What is it?

- 505(b)(2) company with 10 pipeline drug assets
- Spun-out of Imprimis June 2017 (\$20M Series A)
- Strong management team with a history of success

Why is it important?

- Imprimis holds passive 27% equity stake in Eton
- 6% royalty on potential sales of Imprimis contributed patent-pending drug candidates

What is the opportunity?

- 3.5M ownership interest in Eton by Imprimis
- Royalty opportunity for the following candidates:
 - Synthetic corticotropin: infantile spasms
 - Injectable pentoxifylline: peyronie's disease

Surface Pharmaceuticals, Inc. Subsidiary



What is it?

- 505(b)(2) company with three pipeline drug assets
- Focus on ocular surface disease market (Dry Eye)
- Strong management and Board of Directors team with a history of success
- May pursue spin-off transaction similar to Eton

Why is it important?

- Surface is a subsidiary of Imprimis
- 6% royalty on potential sales of Imprimis contributed drug candidates targeting the three areas of dry eye disease: chronic, episodic and refractory

What is the opportunity?

- 3.75M ownership interest in Surface by Imprimis
- Royalty opportunity for three unique drug candidates for up to five separate indications, each with a billion dollar market opportunity

Park Compounding, Inc. Subsidiary



24% of Q3-2017 Revenues



What is it:

- Customizable pharmaceutical compounding wholly owned subsidiary
- Focused on integrative and other medicines for oncology, autoimmune diseases and chronic infectious diseases
- Incubator of new drug formulation ideas from physician customers

Why is it important:

- Large, growing and loyal customer base
- Cash flow generating revenues

What is the opportunity:

- Add new products and expand customer base
- Focus on higher volume and chronic care formulations



Summary



imprimis_{Rx} Value Summary



Largest Ophthalmology Compounding Business in the US

Disrupting the U.S. ophthalmic drug markets with novel compounded formulations

- Ophthalmic Surgery \$1B market
- Glaucoma \$2B+ market
- Dry Eye \$2B market
- Over 1,700 ophthalmology customers and growing



Products and Market Share

- IP focused; 60+ patents or pending patents (US & Int'l) for our formulations
- Consistent growth in ophthalmology compounding market
- Products offer unique value propositions at lower costs



Growth and Profitability

- Strong revenue growth from new formulations expected in 2018
- Plans to significantly expand average revenue per order/surgery during 2018
- Management team focused on near term profitability and value creation
- FDA registered cGMP 503B facility opening new account opportunities; increased efficiency




Balance Sheet Value from Spin-Out Equity and Royalties

Equity ownership / royalty interest in two 505(b)(2) drug companies with rich pipelines

- Park Compounding: drug formulation incubator
- Eton Pharma: Billion dollar market potential and a strong management team
- Surface Pharma: Billion dollar market potential and a strong management team

Company Profile



Trading symbol: **NASDAQ: IMMY**

Price per share (12-5-2017): **\$1.82**

Stock price range (52-week): **\$1.35 - \$4.69**

Avg. daily Q4 trading volume: **595,000 shares**

Market cap: **\$37 million**

Shares Outstanding: **20.5 million**

Insider Beneficial Ownership: **13%**

*Participation by CEO, CFO, Director in Dec 2016 financing

Corporate headquarters: **San Diego, CA**

Facilities: **Irvine, CA & Ledgewood, NJ**

Website: **www.ImprimisRx.com**

imprimis Rx






References and Appendix



References

1. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May).
2. Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from <https://www.statista.com/statistics/271478/number-of-lasik-surgeries-in-the-us/>
3. Imprimis Pharmaceuticals internal business data, including IMS data, 2015-2017
4. IMV Medical Information Division, Inc. Benchmark Report MR2013 (2013, July). Retrieved December 15, 2016.
5. Endodontic Facts by the American Association of Endodontists. (n.d.). Retrieved January 07, 2017, from <http://www.aae.org/about-aae/news-room/endodontic-facts.aspx>
6. Friedman, J. W. (2007, September). The Prophylactic Extraction of Third Molars: A Public Health Hazard. Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1963310/>
7. US Market Report Suite for Gastrointestinal Endoscopic Devices 2017 - MedSuite. (2016, August 01). Retrieved January 08, 2017, from <https://www.idataresearch.com/product/us-market-report-suite-for-gastrointestinal-endoscopic-devices-2017-medsuite/>
8. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from <http://www.webmd.com/men/features/vasectomy-risks-benefits>
9. Elmore, J. G., MD, Longton, G. M., MS, & Carney, P. A., PhD. (2015, March 17). Diagnostic Concordance in Interpreting Breast Biopsies. Retrieved January 08, 2017, from <http://jamanetwork.com/journals/jama/fullarticle/2203798>
10. Voigt, J., & Mosier, M. (2013, September). A powered bone marrow biopsy system versus manual methods: a systematic review and meta-analysis of randomised trials. Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756462/>
11. Irwin, K. (2012, December 10). Prostate cancer now detectable using imaging-guided biopsy, UCLA study shows. Retrieved January 08, 2017, from <http://newsroom.ucla.edu/releases/prostate-cancer-now-detectable-241575>
12. Sklavos, M. M., Spracklen, C. N., Saftlas, A. F., & Pinto, L. A. (2014, February 23). Does Loop Electrosurgical Excision Procedure of the Uterine Cervix Affect Anti-Müllerian Hormone Levels? Retrieved January 08, 2017, from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953513/>
13. Centers for Disease Control and Prevention - United States, 2013. (2016, November 24). Retrieved January 07, 2017, from <https://www.cdc.gov/mmwr/volumes/65/ss/ss6512a1.htm>
14. ASPS 2015 Plastic Surgery Statistics Report - American Society of Plastic Surgeons. (2015). Retrieved January 8, 2017, from <https://d2wirczt3b6wjw.cloudfront.net/News/Statistics/2015/plastic-surgery-statistics-full-report-2015.pdf>
15. Glaucoma Research Foundation. Glaucoma Facts and Stats. Retrieved February 9, 2017 from <http://www.glaucoma.org/glaucoma/facts-statistics/glaucoma-facts-and-stats.php>
16. Schott, Chris, J.P. Morgan, "Eye' deally Positioned to Expand the Dry Eye Market . . ." August 14, 2017

Drug Combination IP



Published Clinical Data

Tyson, S. L., et al. (2017, January). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. *Current Opinion in Ophthalmology*.

No major intraoperative complications associated with the transzonular injection technique. There were no cases of postoperative endophthalmitis. Rates of infection and inflammation reported in this retrospective review of 1,541 cases from 922 patients receiving a transzonular injection of Tri-Moxi-Vanc for prophylaxis after cataract surgery appear similar to reported rates with alternative prophylactic therapies such as topical drops.⁵

Fisher, B. L., & Potvin, R. (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. *Current Pharmaceutical Design*.

Review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the Dropless® approach. Both groups expressed similar satisfaction with surgery, but patients who received Dropless® preferred the overall experience ($P=0.01$).⁴

Lindstrom, R.L., et al. (2017, February). Dropless Cataract Surgery: An Overview. *Current Pharmaceutical Design*.

Compliance issues are diminished with Dropless Therapy compared to standard post-surgery topical drop regimens. Cost savings to patients can range from \$200 to \$600 per cataract procedure. Staff time is reduced without patient, insurance and pharmacy callbacks about eye drop substitutions and confusion over topical regimens. A retrospective review of Dropless Therapy cases found no postoperative endophthalmitis. Post-surgery infection and inflammation rates were similar to reported rates with other alternative prophylactic therapies, such as topical drops.⁶



**Imprimis Pharmaceuticals
(NASDAQ: IMMY)**

12264 El Camino Real, #350
San Diego, CA 92130
(858) 704-4040

ir@imprimispharma.com
www.imprimisrx.com



